Related references
Note: Only part of the references are listed.Biologic treatments for elderly patients with psoriasis
Mami Momose et al.
JOURNAL OF DERMATOLOGY (2017)
Herpes zoster in psoriasis patients treated with tofacitinib
Kevin L. Winthrop et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments
Joseph G. Kamel et al.
DRUGS & AGING (2017)
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Kresimir Kostovic et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
Zenas Z. N. Yiu et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period
M. Megna et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study
Akihiko Asahina et al.
JOURNAL OF DERMATOLOGY (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis
April W. Armstrong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis
C. Phan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
N. Punwani et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use
Junko Takeshita et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis
Logan S. D'Souza et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Herve Bachelez et al.
LANCET (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)
Peter H. Schafer et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients
Stefano Piaserico et al.
ACTA DERMATO-VENEREOLOGICA (2014)
THU0227 Pooled Analysis of Clinical Safety Data for ASP015K, a Novel Jak Inhibitor in Development for Treatment of Autoimmune Diseases
J. Garg et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
Yong Liu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Managing Moderate-to-Severe Psoriasis in the Elderly
Nicola Balato et al.
DRUGS & AGING (2014)
Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis
Mitsuha Hayashi et al.
JOURNAL OF DERMATOLOGY (2014)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
B. Strober et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center
Faranak Kamangar et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Ken Garber
NATURE BIOTECHNOLOGY (2013)
Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States Findings From the National Psoriasis Foundation Surveys, 2003-2011
April W. Armstrong et al.
JAMA DERMATOLOGY (2013)
Tofacitinib and Other Kinase Inhibitors in the Treatment of Psoriasis
K. Ortiz-Ibanez et al.
ACTAS DERMO-SIFILIOGRAFICAS (2013)
Adverse drug reactions in the elderly
Dhriti K. Brahma et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2013)
Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy
Gregorio Carretero
ARCHIVES OF DERMATOLOGY (2012)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
Jordan S. Fridman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation
Ivan S. Grozdev et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
Betty Y. Chang et al.
JOURNAL OF IMMUNOLOGY (2009)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progress in Understanding the Immunopathogenesis of Psoriasis
R. K. H. Mak et al.
ACTAS DERMO-SIFILIOGRAFICAS (2009)
Th17 cells: a new fate for differentiating helper T cells
Zhi Chen et al.
IMMUNOLOGIC RESEARCH (2008)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
Elizabeth J. Horn et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Immunopathogenesis of psoriasis
Brian J. Nickoloff et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2007)
Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
Sebastian Schneeweiss et al.
ARTHRITIS AND RHEUMATISM (2007)
Survival and safety of treatment with infliximab in the elderly population
H Chevillotte-Maillard et al.
RHEUMATOLOGY (2005)
Share Paper
